AbbVie Inc. is 215.9x more valuable than Nurix Therapeutics, Inc. by market capitalization ($399.47 B vs $1.85 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NRIX | ABBV |
|---|---|---|
| Market cap | $1.85 B | $399.47 B |
| US-listed rank | #2152 | #28 |
| Revenue (latest FY) | $83.98M | $61.16B |
| Net income (latest FY) | -$264.46M | $4.23B |
| Net margin | -314.9% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 511 | 1,008 |
AbbVie Inc. is 215.9x more valuable than Nurix Therapeutics, Inc. by market capitalization ($399.47 B vs $1.85 B).
In their latest fiscal years, Nurix Therapeutics, Inc. reported $83.98M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Nurix Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.